
5.8K
Downloads
24
Episodes
From business publication BioProcess International comes The BioProcess Insider Expression Platform (BIEP). Editor Dan Stanton takes a look beyond the nuts and bolts of the biomanufacturing industry and speaks to some of the pioneers and thought leaders turning production on its head. www.bioprocessinsider.com
Episodes

Friday Aug 12, 2022
Friday Aug 12, 2022
This episode of the BioProcess Insider Expression Platform (BIEP) podcast brings you an in-depth conversation with Stuart Curbishley, head of business and project development, advanced therapies at University of Birmingham and Ivan Wall, CEO, Four-Plus and director of the National Training Center for advanced therapies manufacturing.
We delve deep into the challenges concerning training talent in the advanced therapy and wider biopharma space, potential solutions that could filter the staffing bottleneck, and how the respective institutions are responding to these issues.

Wednesday Jul 20, 2022
Snippets from BIO: Lumen CEO talks edible antibodies
Wednesday Jul 20, 2022
Wednesday Jul 20, 2022
Another interview taken from the BioProcess International Theater at BIO, in June 2022.
This time, I sat down with Brian Finrow, the Co-Founder and CEO of Lumen Biosciences - a biotech looking to unlock the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology.
The firm is developing ‘oral antibodies’ using its platform based on spirulina – the protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – to create tiny factories that churn out therapeutic antibodies.

Friday Jul 15, 2022
Snippets from BIO: Cytiva’s Emmanuel Ligner on Biopharma resilience
Friday Jul 15, 2022
Friday Jul 15, 2022
Emmanuel Ligner, CEO of self-described bioprocess critical actor Cytiva, talks us through the changing biomanufacturing landscape and unveils his firm’s sustainability report during a fireside chat at the BioProcess International Theater at BIO in June

Friday Jul 08, 2022
Snippets from BIO 22: Fujifilm Diosynth’s Martin Meeson
Friday Jul 08, 2022
Friday Jul 08, 2022
In the first of my series of interviews from BIO 2022 in San Diego, I speak with Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, one of the most prominent contract development and manufacturing organizations (CDMOs).
He talks about the CDMO's part in battling COVID-19, the major capital expenditure projects underway at facilities in Denmark, North Carolina, and elsewhere, and Fujifilm's presence in the advanced therapies space, and why it has chosen to invest in mRNA, gene therapies, and allogeneic -- but not autologous -- cell therapy capabilities.

Wednesday May 25, 2022
Opening the gates for women in biotech, with Nadine Ritter
Wednesday May 25, 2022
Wednesday May 25, 2022
There is no lack of talented women in the biotech space but the gates blocking their progression must be open for them to fully realize their potential.
“Career development is an integral part of DEI because it’s diversity inclusion at the starting gate,” rather than just a tick-box exercise among the C-suite, said Nadine Ritter, president and analytical advisor at Global Biotech Experts at a DEI coffee morning at BPI Europe in Vienna. “It will never really change at the top unless we remediate the gates [below].”
This podcast is the full conversation with BioProcess Insider reporter Millie Nelson

Wednesday May 04, 2022
The changing dynamics between drug sponsors and their CDMO partners
Wednesday May 04, 2022
Wednesday May 04, 2022
Over the past decade, the relationships drug developers have with their third-party biomanufacturers has evolved from relatively simple transactional services to integrated and complex strategic partnerships.
This podcast replays a panel discussion from EBD's BIO EUROPE Spring event where editor Dan Stanton discusses the changing way pharma works with CDMOs with delegates from Samsung Biologics, Catalent, and AGC Biologics.
Topics covered include: The history of CDMOs, M&A within the industry, the advent of new modalities and, of course, the COVID-19 pandemic.

Friday Nov 05, 2021
Dendreon‘s leap into the cell therapy CDMO space
Friday Nov 05, 2021
Friday Nov 05, 2021
Dendreon, a pioneer in the cell therapy space through its commercial product Provenge, has relaunched itself as a contract development and manufacturing organization (CDMO).
BioProcess Insider speaks with Maria Cho, the VP of Business Development and Corporate Strategy, about Dendreon's strategic growth efforts in the cellular immunotherapy space and how it is embracing its proven success in the field to support others.

Monday Aug 09, 2021
GSK's Digital Twin Approach to Vaccine Development, with Matt Harrison
Monday Aug 09, 2021
Monday Aug 09, 2021
A digital twin is a virtual representation that serves as the real-time digital counterpart of a physical object or process. Biopharma giant GlaxoSmithKline (GSK) has adopted this technology to advance its vaccine development and manufacturing division.
A year after partnering with Siemens and Atos to pilot a digital twin in order to create a real-time simulation of the entire vaccine manufacturing process, we sat down (virtually, sadly) with Matt Harrison, head of Sciences, Digital Innovation and Business Strategy at GSK to discuss the current status of this project.
Keep up with BioProcess Insider on our website.
Follow us on LinkedIn and Twitter:

Monday May 10, 2021
On Board the Cell Shuttle with Cellares' Fabian Gerlinghaus
Monday May 10, 2021
Monday May 10, 2021
Having raised $82 million in its latest funding round, tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle.
We spoke with co-founder and CEO Fabian Gerlinghaus about the current limitations in CAR-T production and how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space
Keep up with BioProcess Insider on our website.
Follow us on LinkedIn and Twitter:

Wednesday Apr 21, 2021
The Future of Cell and Gene Therapies, with E&Y’s Adlai Goldberg
Wednesday Apr 21, 2021
Wednesday Apr 21, 2021
The cell and gene therapy sector is on the cusp of flourishing in the vast pharma landscape. Money is flowing in, manufacturing challenges are being overcome, people are actually being treated and cured. Even COVID-19 may be seen as a driving force for the burgeoning sector. But what does the future hold? Ernst & Young’s Adlai Goldberg describes the steps industry must take to advance the advanced therapy space and how it must move to balance the individualized autologous approach with more sustainable allogeneic products.
Keep up with BioProcess Insider on our website.
Follow us on LinkedIn and Twitter: